导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.14% | 2889/4766 |
| 近一周 | -1.24% | 2296/5457 |
| 近一月 | -2.41% | 935/5411 |
| 近一季 | -6.16% | 1975/5229 |
| 近半年 | -4.08% | 2872/4923 |
| 近一年 | -0.20% | 2641/4393 |
| 近两年 | 36.13% | 2054/2948 |
| 近三年 | 23.11% | 1353/2248 |
| 成立以来 | 66.93% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.59% 1865/4961 |
7.68% 2677/5312 |
- - |
- - |
| 2025 | 12.81% 2678/4813 |
0.64% 1802/3635 |
2.57% 1484/4076 |
6.92% 3493/4524 |
2.21% 1041/4813 |
| 2024 | 16.80% 763/3463 |
2.75% 718/2808 |
-1.07% 912/3014 |
16.41% 1464/3129 |
-1.29% 1646/3463 |
| 2023 | -2.71% 600/2656 |
5.66% 762/2280 |
-1.88% 537/2385 |
-1.27% 501/2515 |
-4.94% 1217/2655 |
| 2022 | -13.75% 340/2207 |
-10.82% 430/1919 |
3.98% 1071/2016 |
-10.93% 469/2113 |
4.41% 550/2208 |
| 2021 | -2.69% 868/1822 |
-1.18% 446/1255 |
2.20% 1011/1330 |
-8.78% 1156/1466 |
5.64% 279/1822 |
| 2020 | 34.91% 432/1250 |
-7.88% 578/1028 |
15.44% 502/1067 |
11.54% 437/1164 |
13.73% 336/1184 |
| 2019 | - - |
- - |
-3.52% 401/804 |
2.24% 312/850 |
10.39% 141/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国联央视财经50ETF VS. 长安沪深300非周期A(740101) |